Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease. - Wikidata - awgldk - TriplyDB

Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease.

Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease.

http://www.wikidata.org/entity/Q37031522

about

Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies The complex relationship between depression and dementia.Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics.Pharmacogenomics and treatment for dementia induced by Alzheimer's disease.Genomics and pharmacogenomics of dementia.Epigenetic drug discovery for Alzheimer's disease.Monoaminergic neuropathology in Alzheimer's disease.Association of CYP2D6*4 genetic polymorphism on the metabolism of Donepezil with Alzheimer's disease in Indian population.Clinical Response to Donepezil in Mild and Moderate Dementia: Relationship to Drug Plasma Concentration and CYP2D6 and APOE Genetic Polymorphisms.Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants.The genetics of Alzheimer's disease

P2860

Q26769957-A431524B-50DC-433B-90C9-016666A8D68E Q34574950-F8D227EC-85EB-479F-9233-9092B4A07C4C Q35852564-221F8DAE-7B83-44E0-AAC7-004EBDCE843E Q37205951-5A058E03-BBE1-4DE8-A4AB-205939826561 Q37780790-3C9694D4-B2F7-45F2-B305-8ED35D5A65D6 Q38225708-782EA08B-5A3B-4E41-9A09-AB717111D3C6 Q38809649-87CB5105-9F7B-4E13-BE2E-CA515C0962AC Q45774152-6FCD147D-00CC-4EEB-B01B-43023E786410 Q47919475-6620E04A-E9AC-40C6-AD79-A45F2BE800A8 Q55266735-7CFDE707-2AA9-4093-9962-B8B8B30B745F Q58914116-E65B0C8F-80ED-4374-9D8E-559B71681433

P2860

Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease.

http://www.wikidata.org/entity/Q37031522

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2007

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease.

@en

Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease.

@nl

type

label

Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease.

@en

Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease.

@nl

prefLabel

Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease.

@en

Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease.

@nl

P1433

Q37031522-948D5CEF-DF02-44D2-BD87-3D8EFB593AEE

P1476

Q37031522-788862E2-C688-4FBA-8A94-59C3DB6884A1

P2860

Q37031522-01491ECC-664B-4714-9183-4CF8CF29759F

Q37031522-05706C6A-2808-46FB-A788-83E5EDBABCE6

Q37031522-07B17BB1-16BD-456E-A348-A3B799348D07

Q37031522-15B70F1C-ECE8-412D-91A5-8EE313623353

Q37031522-1B32038B-2778-4E5A-9E3E-62B2E47BDC2C

Q37031522-1FEC8A29-2F3A-4071-88E3-7FBB23F5DDC9

Q37031522-2139712D-8DE7-4C99-813B-170399E99A71

Q37031522-2214A7D5-1520-4EBF-9841-E3ED40F7C616

Q37031522-2898AA97-76B3-486A-811C-6EE9652C91B5

Q37031522-2920BC74-7716-4FDA-A1EC-7B91B2E2B761

P2888

Q37031522-678C3A34-6077-41E5-B18F-60E994A7BD57

P304

Q37031522-44DBA06C-E2DA-4021-BD65-32A1006D77EB

P31

Q37031522-DA9D5934-A941-43CE-A40F-5D9C9A896B3E

P356

Q37031522-9DAE6F13-5854-4169-A7FD-2461DE57D137

P433

Q37031522-9C34CD64-F138-43AE-A0C0-D8E99AE3DFCC

P478

Q37031522-F9D165F9-FDA7-493B-B6F6-42CC6569F883

P50

Q37031522-7F792776-E624-4918-B10C-2A6F96ED21BB

P577

Q37031522-9D620EF7-568C-4B3B-B8E7-E1389348E04F

P698

Q37031522-F8B03308-CA0B-4600-99CA-7521EDCA29D6

P921

Q37031522-A71473CA-CE37-4699-8D9F-C174454FC3AF

P356

P1433

Molecular Diagnosis and Therapy

P1476

Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease.

@en

P2860

Finishing the euchromatic sequence of the human genome

Reliability and Validity of NINCDS-ADRDA Criteria for Alzheimer's Disease

Catalog of 680 variations among eight cytochrome p450 ( CYP) genes, nine esterase genes, and two other genes in the Japanese population

CYP2C9 allelic variants: ethnic distribution and functional significance

Deciphering the genetic basis of Alzheimer's disease

Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta ); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity.

APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease.

Prevalence of potentially inappropriate medication use in elderly patients: comparison between general medical and geriatric wards.

Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease.

Impact of genomics on drug discovery and clinical medicine.

P2888

P304

385-405

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/BF03256262

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Ramón Cacabelos

P577

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18078356

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease